WATERTOWN, Mass.–Marrow Therapeutics has launched with $173 million in Series A and Series B financing to develop genetic medicines targeting bone marrow disorders, including sickle cell disease and beta thalassemia.
The Watertown biotechnology company is developing a proprietary platform designed to deliver genetic therapies directly to bone marrow, potentially addressing safety, manufacturing, and accessibility challenges associated with existing treatments for serious blood disorders.
Marrow was founded by Scion Life Sciences and raised $53 million in Series A financing co-led by Scion and venBio.
The company subsequently secured $120 million in Series B funding led by OrbiMed, with participation from existing investors and several new backers.
Additional investors included RTW Investments, Surveyor Capital, Opaleye, NEXTBio Capital, Affinity Advisors, KKR, Spruce Street Capital, and Columbia Threadneedle Investments.
Marrow is led by President and Chief Executive Officer Romesh Subramanian, alongside Chief Scientific Officer Tim Weeden and Chief Operating Officer and Chief Technology Officer John Najim.
The company’s research focuses on developing engineered antibodies capable of transporting therapeutic molecules directly into bone marrow cells.
Its proprietary Transferrin Antibody Bioconjugate (TAB) platform uses antibodies designed to bind to transferrin receptor 1, a protein involved in cellular iron uptake.
By targeting this receptor, Marrow aims to deliver genetic medicines to bone marrow while limiting exposure to other tissues.
The approach is intended to overcome some of the limitations of earlier genetic medicine technologies, including complex manufacturing processes, potential safety risks, and barriers to patient access.
Marrow’s lead experimental treatment, MAR-101, is being developed for sickle cell disease and beta thalassemia, two inherited blood disorders that affect hemoglobin production.
The therapy is designed to reduce the activity of BCL11A, a protein involved in suppressing fetal hemoglobin production.
By lowering BCL11A activity, researchers aim to reactivate fetal hemoglobin, which could help compensate for defective adult hemoglobin in patients with these conditions.
MAR-101 is currently undergoing studies intended to support a future Investigational New Drug application.
“We’re at a pivotal moment in genetic medicine and its application in severe blood disorders – the field has validated key targets and shown that genetic approaches can work, but we need to solve the safety and accessibility challenges to truly transform patient outcomes,” said Romesh Subramanian, President and Chief Executive Officer of Marrow Therapeutics.
“By precisely targeting the bone marrow, we’re able to deliver the potential of genetic medicines and provide sustained benefit, while simultaneously avoiding the risks that have constrained earlier approaches. Our preclinical data gives us tremendous confidence in this strategy, and we’re excited to move toward the clinic with a platform designed to address a broad range of severe hematological diseases.”
The company said its technology builds on research involving transferrin receptor biology and antibody-based drug delivery.
One challenge associated with targeting transferrin receptors is the potential to interfere with normal red blood cell production, which can increase the risk of anemia.
Marrow said its platform has been engineered to improve tissue targeting while reducing unintended biological effects.
However, the safety and effectiveness of the approach have not yet been established in human clinical trials.
In addition to MAR-101, the company is developing several other programs targeting hematological and bone marrow diseases.
OrbiMed, which led the Series B financing, said the company’s platform could support multiple therapeutic applications.
“Marrow represents a differentiated technology platform, experienced leadership, and the potential to provide effective and safe treatment options for severe blood disorders,” said Mona Ashiya, General Partner at OrbiMed.
“I am excited to work with this experienced team that has brought first-generation TfR1 platforms into the clinic. What is particularly compelling is their ‘pipeline in a product’ strategy. MAR-101 validates the platform across sickle cell disease and beta thalassemia with a single therapeutic approach, while their growing pipeline across additional blood and bone disorders demonstrates the true versatility and long-term value of this platform.”
Marrow has assembled an executive team with experience in genetic medicine development, antibody engineering, and pharmaceutical manufacturing.
Weeden, the company’s Chief Scientific Officer, brings expertise in transferrin receptor biology and the development of antibody and nucleic acid therapies.
Najim, who serves as Chief Operating Officer and Chief Technology Officer, oversees operational and manufacturing-related activities, including chemistry, manufacturing, and controls.
Gavriel Mullokandov serves as Founder and Vice President of Corporate Development, supporting the company’s strategic growth and development programs.
Marrow also announced the appointment of Art Levin, Founding Chief Scientific Officer of Avidity Biosciences, to its Board of Directors.
Stuart Orkin, M.D., David G. Nathan Distinguished Professor of Pediatrics at Harvard Medical School and a Howard Hughes Medical Institute Investigator at Boston Children’s Hospital, has joined the company’s Scientific Advisory Board.
Scion Life Sciences, which helped establish Marrow, said the company’s technology was developed using lessons from earlier transferrin receptor-targeting platforms.
“From its inception, Marrow has had the potential to become a transformative and valuable company. This has been made possible by an experienced and knowledgeable leadership team that has consistently displayed the scientific rigor and operational excellence we look for at Scion,” said Aaron Kantoff, Co-Founder and Managing Partner at Scion Life Sciences.
“Marrow has optimized its proprietary bone marrow-targeting platform using lessons learned from validated first-generation TfR1 platforms targeting other tissues and organs. By leveraging well-understood biology, the company is in a great position to create paradigm-shifting therapies for patients dealing with severe blood disorders of high unmet need.”
The company plans to advance its lead program toward clinical testing while expanding development of additional genetic medicines for serious blood and bone marrow disorders.
Scion indicated that Marrow expects to begin moving its programs into clinical development in 2027.
The $173 million financing provides the company with capital to support its research, preclinical development, and preparations for human clinical trials.


